Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are linked to cancer development.
• Known mutations in IDH1 and IDH2 lead to the production of the oncometabolite R(-)-2-hydroxyglutarate (2HG).
• The precise mechanisms by which IDH mutations contribute to tumorigenesis are still being elucidated.

Purpose of the Study:

• To identify novel mutations in IDH1 and IDH2 that result in 2HG production.
• To investigate the functional consequences of newly identified IDH mutations.
• To explore alternative mechanisms of IDH-related tumorigenesis beyond 2HG production.

Main Methods:

• Genomic analysis to identify IDH mutations in cancer samples.
• Cellular assays to measure 2HG production by mutant IDH enzymes.
• Enzymatic assays to assess NADPH production and wild-type activity of IDH mutants.

Main Results:

• Three new IDH1 mutations (R100, G97, Y139) were identified that stereospecifically produce the R-enantiomer of 2HG.
• Certain IDH1 single nucleotide polymorphisms (SNPs) and other mutations did not increase 2HG levels and retained wild-type function.
• Rare IDH mutations in lymphoma and thyroid cancer showed loss of function without elevated 2HG, suggesting alternative oncogenic pathways.

Conclusions:

• IDH mutations contribute to cancer through either neomorphic 2HG production or loss of normal enzymatic activity.
• The study expands the spectrum of known 2HG-producing IDH mutations.
• Metabolite screening is a valuable approach for identifying tumors with potentially oncogenic IDH mutations.